DNLI

Denali Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 2/10
  • Value↑ 5/10
Denali Therapeutics sales and earnings growth
DNLI Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -7.46%
  • FCF Y/Y↓ -9.06%
Denali Therapeutics gross and profit margin trends
DNLI Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -31.66%
Denali Therapeutics net debt vs free cash flow
DNLI Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Denali Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks